Valbiotis SA (ALVAL) AI Stock Analysis

• Market Cap: €24.87M
• Dividend Yield: N/A
• Average Volume (3M): 112.19K
• Price to Earnings (P/E): ―
• Beta (1Y): 0.91
• Revenue Growth: N/A
• EPS Growth: N/A
• Country: FR
• Employees: 44
• Sector: Healthcare
• Sector Strength: 45
• Industry: Biotechnology
• EPS (TTM): -0.19
• Shares Outstanding: 23,698,235
• 10 Day Avg. Volume: 162,174
• 30 Day Avg. Volume: 112,190
• PEG Ratio: -0.35
• Price to Book (P/B): 2.32
• Price to Sales (P/S): 137.18
• P/FCF Ratio: -2.03
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: N/A
• Price Target Upside: N/A
• Rating Consensus: N/A
• Number of Analyst Covering: 0
• EPS Forecast (FY): N/A
• Revenue Forecast (FY): N/A

• Rating: 49 Neutral
• Price Target: €1.00 ▲(38.89% Upside)

The score is weighed down primarily by weak financial performance—ongoing losses and worsening negative free cash flow—along with a negative P/E that reflects lack of profitability. Technicals are a partial offset due to a clear uptrend above major moving averages, but overbought RSI/Stoch readings temper the benefit.

Positive Factors

Scientific R&D Focus

Valbiotis' emphasis on scientifically substantiated nutritional solutions and clinical evaluation builds a durable competitive advantage. Clinical data and formulation know-how increase credibility with healthcare professionals and partners, raising barriers to entry and supporting long-term commercial adoption.

Prevention Market Positioning

The company's clear focus on prevention and health maintenance targets chronic metabolic and cardiovascular areas with ongoing, recurring demand. This positioning supports sustainable product demand and recurring revenue potential if clinical efficacy is validated and consumer trust is maintained over the medium term.

Relatively Stable Balance Sheet

Reported manageable leverage and a healthy equity share of assets give Valbiotis greater financial flexibility than highly indebted peers. This relative balance-sheet resilience can extend runway for clinical work and commercialization, reducing short-term refinancing pressure while strategy execution continues.

Negative Factors

Persistent Negative Margins

Sustained negative gross and net margins, including a negative gross profit in 2024, point to structural profitability issues. Long-term inability to generate positive margins will force continued external funding, constrain reinvestment in R&D and commercialization, and raise dilution risk for shareholders.

Declining and Inconsistent Revenue

The company's inconsistent top-line and a marked revenue decline in 2024 undermine scaling prospects and weaken commercial validation. Persistent revenue volatility complicates forecasting, reduces bargaining power with distributors or partners, and raises execution risk for long-term growth plans.

Worsening Cash Flow and Funding Reliance

Consistent negative operating and free cash flow, worsening in 2024, indicates reliance on external financing to fund operations. Continued FCF deterioration and rising net debt erode financial flexibility, heighten refinancing and dilution risk, and could constrain strategic investments if markets tighten.

Valbiotis SA Business Overview & Revenue Model

Company Description

Valbiotis SA engages in the research and development of health nutrition products to prevent and combat metabolic and cardiovascular diseases. The company develops TOTUM-63 that is in Phase II/III clinical trials for the treatment of type 2 diabetes; TOTUM-070, which is in Phase II clinical trials to treat hypercholesterolemia; and TOTUM-854 that is in Phase II/III clinical trials for arterial hypertension. It also develops TOTUM-448 for the treatment of patient with non-alcoholic fatty liver disease. It has a strategic partnership with Nestlé Health Science. Valbiotis SA was incorporated in 2014 and is headquartered in Périgny, France.

How the Company Makes Money

Valbiotis generates revenue through the commercialization of its health products, which include dietary supplements and functional foods designed to aid in the management of metabolic disorders. The company's revenue model relies on direct sales of its products to consumers as well as partnerships with distributors and retailers. Additionally, Valbiotis may engage in collaborations with pharmaceutical companies for the development of innovative health solutions, which can provide further revenue through licensing agreements and joint ventures. The company focuses on building significant partnerships in the health sector, enhancing its market reach and influence, which contributes to its earnings.

Valbiotis SA Financial Statement Overview

Summary

Income statement and cash flow are weak: revenue declined in 2024, margins are deeply negative, and operating/free cash flow remain negative and worsening, indicating reliance on external funding. The balance sheet is comparatively steadier with manageable leverage, but declining equity and rising net debt add risk.

Income Statement

Valbiotis SA has shown inconsistent revenue growth with a significant decline in 2024. The company has maintained negative margins across all years, indicating a struggle to achieve profitability. The gross profit margin is negative for 2024, and net profit margins remain deeply negative. These factors point to persistent operational challenges.

Balance Sheet

The balance sheet reveals a manageable debt-to-equity ratio and a relatively stable equity ratio, with stockholders' equity maintaining a healthy proportion of total assets. However, declining equity levels over the years and increasing net debt are concerns that could impact financial stability.

Cash Flow

Valbiotis SA's cash flow statement highlights negative free cash flow, with operating cash flow consistently negative, indicating reliance on external financing. The free cash flow has worsened in 2024 compared to previous years, and a declining free cash flow to net income ratio emphasizes cash flow challenges.

Breakdown	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	175.00K	4.73M	785.00K	298.00K	3.09M
Gross Profit	-2.44M	2.69M	767.00K	282.00K	3.09M
EBITDA	-9.17M	-6.41M	-11.13M	-9.14M	-2.37M
Net Income	-10.03M	-7.37M	-12.31M	-8.68M	-3.83M
Balance Sheet
Total Assets	19.61M	33.31M	27.17M	28.48M	21.00M
Cash, Cash Equivalents and Short-Term Investments	11.58M	25.02M	20.83M	21.82M	14.59M
Total Debt	5.72M	6.88M	7.18M	7.59M	7.01M
Total Liabilities	9.24M	13.71M	13.86M	14.25M	13.93M
Stockholders Equity	10.37M	19.60M	13.31M	14.23M	7.15M
Cash Flow
Free Cash Flow	-11.80M	-8.30M	-9.48M	-7.58M	2.36M
Operating Cash Flow	-11.54M	-8.06M	-9.19M	-7.16M	2.69M
Investing Cash Flow	-61.00K	-250.00K	-197.00K	-7.00K	-332.00K
Financing Cash Flow	-1.84M	12.49M	8.40M	14.40M	4.19M

Valbiotis SA Technical Analysis

• Technical Analysis Sentiment: Positive
• Last Price: 0.72
• 50DMA: Positive
• 100DMA: Positive
• 200DMA: Positive
• MACD: Negative
• RSI: Negative
• STOCH: Negative

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For FR:ALVAL, the sentiment is Positive. The current price of 0.72 is below the 20-day moving average (MA) of 0.76, below the 50-day MA of 0.72, and below the 200-day MA of 0.83, indicating a bullish trend. The MACD of 0.07 indicates Negative momentum. The RSI at 70.84 is Negative, neither overbought nor oversold. The STOCH value of 85.09 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for FR:ALVAL.

Valbiotis SA Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
ALPAT	59 Neutral	€8.72M	-6.51	―	―	―	―
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
ALVAL	49 Neutral	€24.87M	-1.73	―	―	―	―
ALDVI	49 Neutral	€24.37M	-3.50	―	―	101.95%	35.55%
SIGHT	45 Neutral	€17.40M	-0.60	―	―	-92.35%	63.25%